SkyQuest Technology Group recently introduced Stem Cell Therapy Market study with in-depth overview, describing about the Product/Industry Scope and elaborates market outlook and status (2025-2032). The market Study is segmented by key regions which is accelerating the marketization. The Stem Cell Therapy Market has witnessed Excellent growth over the past decade and is expected to maintain its upward trajectory.
Global Stem Cell Therapy market size was valued at USD 311.40 million in 2023 and is poised to grow from USD 369.62 million in 2024 to USD 1456.65 million by 2032, growing at a CAGR of 18.70% in the forecast period (2025-2032).
The stem cell therapy market is experiencing quite a significant growth, driven by the increase in prevalence of chronic diseases among the global population and exploration and incorporation of stem cell-based therapy as outcome-based approach for treatment of these diseases. The market also finds itself in a suitable growing environment due to the rising regulatory support and the growth in demand among the masses for regenerative medicine.
Get a Free Sample PDF of the Report – https://www.skyquestt.com/sample-request/stem-cell-therapy-market
Mesenchymal Stem Cells (MSCs) and Induced Pluripotent Stem Cells (iPS)based cell therapies are finding utilization. The market is witnessing increasing applications in various therapeutic areas such as neurology, cardiology, musculoskeletal conditions, etc. However, the huge upfront costs associated with research, clinical trials, and regulatory approvals for developing stem cell therapy and technical challenges associated with its commercialization remain huge restraints for the market.
Detailed Segmentation and Classification of the report (Market Size and Forecast – 2032, Y-o-Y growth rate, and CAGR):
The Stem Cell Therapy Market can be segmented based on several factors, including product type, application, end-user, and distribution channel.
The global stem cell therapy market is segmented into type, therapy, source, route of administration, technology, application, end user, and region.
By type, the market is classified into Totipotent Stem Cells, Multipotent Stem Cells, Pluripotent Stem Cells, Unipotent Stem Cells, Others.
Depending on therapy, it is divided into Allogeneic Stem Cell Therapy and Autologous Stem Cell Therapy.
According to source, the market is categorized into Adult Stem Cells, Embryonic Stem Cells, Mesenchymal Stem Cells (MSCs), and Induced Pluripotent Stem Cells (iPS).
Depending on route of administration, it is divided into Intravenous (IV) Infusion, Intraarticular Injection, Intrathecal Injection, Intradermal Injection, Others.
By technology, the market is classified into Cell Acquisition (Bone Marrow Harvest, Umbilical Blood Cord, Apheresis), Cell Production (Therapeutic Cloning, In-vitro Fertilization, Cell Culture, Isolation), Cryopreservation, Expansion and Sub-Culture.
According to application, the market is categorized into Musculoskeletal Disorders, Wounds & Surgeries, Inflammatory & Autoimmune Diseases, Cardiovascular Diseases, Neurological Disorders, and Others.
By end user, the market is classified into Hospitals, Specialty Clinics, Academic & Research Institutes, and Others.
Regionally, the market is analyzed across North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
Stem Cell Therapy Market – Regional Analysis:
The North America stem cell therapy market emerges as the most dominant stem cell therapy market in the world. The region’s importance can be attributed to advanced healthcare infrastructure, high R&D investments, and the presence of established and prominent biotechnology firms in the region. Support from regulatory frameworks, national regulatory agencies’ approvals for stem cell therapies, and rising prevalence of chronic diseases also adds to market growth.
Asia Pacific is predicted to grow at the highest rate in the stem cell therapy market over the projection period of 2025-2032. The growth in the region is led by the improving healthcare infrastructure and growing burden of chronic diseases in this region. People are becoming more aware day by day about the benefits of regenerative medicine.
Europe held a significant market share in 2024 and is likely to continue so during the forecast period of 2025-2032. Governments of countries in Europe provide great regulatory backing to stem cell therapies. The research infrastructure is advancing, and collaborations between academia and industry are seeing growth. Public and private investments in regenerative medicine are encouraging innovation in mesenchymal and induced pluripotent stem cells.
Top Market Players in Stem Cell Therapy Market are:
Smith & Nephew plc (United Kingdom)
Medipost Co. Ltd. (South Korea)
JCR Pharmaceuticals Co., Ltd. (Japan)
Takeda Pharmaceutical Company Limited (Japan)
Anterogen Co., Ltd. (South Korea)
Corestem, Inc. (South Korea)
Pharmicell Co., Ltd (South Korea)
NuVasive, Inc. (United States)
Holostem SRL (Italy)
Orthofix Medical Inc. (United States)
Stempeutics Research Pvt Ltd. (India)
Regrow Biosciences Pvt Ltd. (India)
Healios KK (Japan)
Mesoblast Ltd. (Australia)
BioRestorative Therapies, Inc. (United States)
Pluri Inc. (Israel)
BrainStorm Cell Inc (United States)
Ayrmid Limited (Gamida Cell) (United Kingdom)
Vertex Pharmaceuticals (ViaCyte, Inc.) (United States)
Kangstem Biotech Co., Ltd. (South Korea)
For a customized report, contact us to request personalization – https://www.skyquestt.com/speak-with-analyst/stem-cell-therapy-market
Recent Developments in Stem Cell Therapy:
In May 2025, Applied StemCell launched two research-use-only hypoimmunogenic hiPSC products. These are ActiCells RUO Hypo hiPSCs and ActiCells RUO TARGATT Hypo hiPSC Knock-in Kit. These product launches serve a broader intention of the company to accelerate allogeneic cell therapy development. They are engineered with B2M/CIITA knockouts to evade immune rejectiona and are genome-editing ready. Both products are isogenic with future GMP versions. This feature will help in providing a smooth transition from research to clinical development.
Medipost had started Phase 3 trials in Japan for CARTISTEM in November 2024. Caristem is Medipost’’s allogeneic stem cell therapy for knee osteoarthritis. It is the first Korean product to skip Phases 1 and 2 with PMDA approval. The trial is scheduled to have 130 patients and a one-year follow-up. The company is also looking into global partnerships and preparing a U.S. submission.
In May 2024, Alloy Therapeutics and Takeda joined a partnership with each other to develop and commercialize Takeda’s iPSC-derived CAR-T and CAR-NK platforms (iCAR-T/NK) for cancer therapy. The platforms create potent, off-the-shelf cell therapies with lower manufacturing costs. Alloy got co-exclusive commercialization rights and will establish a Japanese subsidiary to support the initiative.
Take Action Now: Secure Your Stem Cell Therapy Market Today – https://www.skyquestt.com/buy-now/stem-cell-therapy-market
Forward-Looking Insights
The Stem Cell Therapy Market is set to experience sustained growth, fueled by technological advancements, broader global market access, and rising industry demand. With the industry addressing emerging challenges and capitalizing on new opportunities, it is expected to drive innovation and play a pivotal role in advancing global health and economic progress.
About Company:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact Details:
SkyQuest Technology Group
USA (+1) 351-333-4748
Email: [email protected]
